Barriers and facilitators of exploiting the potential of value-added medicines.
Zsuzsanna Ida PetykóAndras InotaiAnke-Peggy HoltorfDiana BrixnerZoltán KalóPublished in: Expert review of pharmacoeconomics & outcomes research (2020)
Current practices may need to be reconsidered to exploit the full societal benefit of VAMs, including more efficient policies to guarantee market exclusivity for incremental innovation, acknowledgment of a fair price premium based on a specific value framework and the acceptance of low-cost evidence generation methods.